Imatinib alone and in combination for chronic myeloid leukemia

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

Original languageEnglish (US)
Pages (from-to)50-58
Number of pages9
JournalSeminars in Hematology
Volume40
Issue number1
DOIs
StatePublished - Jan 2003

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Targeted Therapy
Imatinib Mesylate
Switzerland
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Imatinib alone and in combination for chronic myeloid leukemia. / Druker, Brian.

In: Seminars in Hematology, Vol. 40, No. 1, 01.2003, p. 50-58.

Research output: Contribution to journalArticle

@article{0482682bc8f247438adeb37500ff726b,
title = "Imatinib alone and in combination for chronic myeloid leukemia",
abstract = "Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.",
author = "Brian Druker",
year = "2003",
month = "1",
doi = "10.1016/S0037-1963(03)70042-0",
language = "English (US)",
volume = "40",
pages = "50--58",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Imatinib alone and in combination for chronic myeloid leukemia

AU - Druker, Brian

PY - 2003/1

Y1 - 2003/1

N2 - Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

AB - Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0037254419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037254419&partnerID=8YFLogxK

U2 - 10.1016/S0037-1963(03)70042-0

DO - 10.1016/S0037-1963(03)70042-0

M3 - Article

C2 - 12563611

AN - SCOPUS:0037254419

VL - 40

SP - 50

EP - 58

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -